Review Article

Review of commercially available nano-drugs and nano-delivery systems: challenges and perspectives

¹ Folium Labs Inc, 4388 rue Saint-Denis bureau, 200-104, Montréal, QC H2J2L1, Canada
² Centre de Recherche Acoustique-Signal-Humain de l’Université de Sherbrooke, Université de Sherbrooke, 2500 Boulevard de l’Université, Sherbrooke, QC J1K2R1, Canada
³ Medelys Laboratories International, 520 McCaffrey Street, Montréal, QC H4T1N1, Canada
⁴ Department of Chemical Engineering, Polytechnique Montréal, 2500 chem. de Polytechnique, Montréal, QC H3C3A7, Canada

^* Corresponding author: domenico.fuoco@polymtl.ca

Received: 13 January 2024
Accepted: 7 August 2024

Abstract

Nano-drugs and nano-delivery systems are rapidly evolving, with new strategies emerging in the current practices. The evolution of these technologies began with modifying the chemical structure, progressing to supramolecular ionic complexes, and culminating in elegant ad hoc delivery systems. Nanoparticles have numerous benefits as a carrier system for delivering therapeutic agents to intra-arterial sites. These benefits include their subcellular size, targeted surfaces, good suspensibility, and uniform dispersity, making them an ideal choice for catheter-based delivery. Despite the advancements made in the field of nano-drugs and nano-delivery systems, there are still some hurdles to overcome in terms of their commercial availability. The current review presents an updated summary of recent advancements in nano-drugs and nano-delivery systems, including their commercial availability. We aim to discuss the present challenges and prospects of commercially available nano-drugs and nano-delivery systems. Here, we provide a precise and informative overview of the current state of these technologies and underscore the potential they hold for future developments. Further, we have categorized commercially available modifications, name, parent company and their main applications in nano-drugs.